Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Selective Histone Deacetylase 6 Inhibition Normalizes B Cell Activation and Germinal Center Formation in a Model of Systemic Lupus Erythematosus.

Ren J, Catalina MD, Eden K, Liao X, Read KA, Luo X, McMillan RP, Hulver MW, Jarpe M, Bachali P, Grammer AC, Lipsky PE, Reilly CM.

Front Immunol. 2019 Oct 25;10:2512. doi: 10.3389/fimmu.2019.02512. eCollection 2019.

2.

Restoration of histone acetylation ameliorates disease and metabolic abnormalities in a FUS mouse model.

Rossaert E, Pollari E, Jaspers T, Van Helleputte L, Jarpe M, Van Damme P, De Bock K, Moisse M, Van Den Bosch L.

Acta Neuropathol Commun. 2019 Jul 5;7(1):107. doi: 10.1186/s40478-019-0750-2.

3.

Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment.

Ma J, Huo X, Jarpe MB, Kavelaars A, Heijnen CJ.

Acta Neuropathol Commun. 2018 Oct 1;6(1):103. doi: 10.1186/s40478-018-0604-3.

4.

Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations.

Gewandter JS, Brell J, Cavaletti G, Dougherty PM, Evans S, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP, Loprinzi C, Richardson P, Lavoie-Smith EM, Wen PY, Turk DC, Dworkin RH, Freeman R.

Neurology. 2018 Aug 28;91(9):403-413. doi: 10.1212/WNL.0000000000006083. Epub 2018 Jul 27. Review.

5.

Understanding the Collaborative Planning Process in Homeless Services: Networking, Advocacy, and Local Government Support May Reduce Service Gaps.

Jarpe M, Mosley JE, Smith BT.

J Public Health Manag Pract. 2019 May/Jun;25(3):262-269. doi: 10.1097/PHH.0000000000000812.

PMID:
29889180
6.

Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth.

Van Helleputte L, Kater M, Cook DP, Eykens C, Rossaert E, Haeck W, Jaspers T, Geens N, Vanden Berghe P, Gysemans C, Mathieu C, Robberecht W, Van Damme P, Cavaletti G, Jarpe M, Van Den Bosch L.

Neurobiol Dis. 2018 Mar;111:59-69. doi: 10.1016/j.nbd.2017.11.011. Epub 2017 Nov 29.

7.

HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients.

Guo W, Naujock M, Fumagalli L, Vandoorne T, Baatsen P, Boon R, Ordovás L, Patel A, Welters M, Vanwelden T, Geens N, Tricot T, Benoy V, Steyaert J, Lefebvre-Omar C, Boesmans W, Jarpe M, Sterneckert J, Wegner F, Petri S, Bohl D, Vanden Berghe P, Robberecht W, Van Damme P, Verfaillie C, Van Den Bosch L.

Nat Commun. 2017 Oct 11;8(1):861. doi: 10.1038/s41467-017-00911-y.

8.

HDAC1,2 inhibition and doxorubicin impair Mre11-dependent DNA repair and DISC to override BCR-ABL1-driven DSB repair in Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia.

Tharkar-Promod S, Johnson DP, Bennett SE, Dennis EM, Banowsky BG, Jones SS, Shearstone JR, Quayle SN, Min C, Jarpe M, Mosbruger T, Pomicter AD, Miles RR, Chen WY, Bhalla KN, Zweidler-McKay PA, Shrieve DC, Deininger MW, Chandrasekharan MB, Bhaskara S.

Leukemia. 2018 Jan;32(1):49-60. doi: 10.1038/leu.2017.174. Epub 2017 Jun 5.

9.

HDAC6 inhibition effectively reverses chemotherapy-induced peripheral neuropathy.

Krukowski K, Ma J, Golonzhka O, Laumet GO, Gutti T, van Duzer JH, Mazitschek R, Jarpe MB, Heijnen CJ, Kavelaars A.

Pain. 2017 Jun;158(6):1126-1137. doi: 10.1097/j.pain.0000000000000893.

10.

Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.

Min C, Moore N, Shearstone JR, Quayle SN, Huang P, van Duzer JH, Jarpe MB, Jones SS, Yang M.

PLoS One. 2017 Jan 6;12(1):e0169128. doi: 10.1371/journal.pone.0169128. eCollection 2017.

11.

Development of Improved HDAC6 Inhibitors as Pharmacological Therapy for Axonal Charcot-Marie-Tooth Disease.

Benoy V, Vanden Berghe P, Jarpe M, Van Damme P, Robberecht W, Van Den Bosch L.

Neurotherapeutics. 2017 Apr;14(2):417-428. doi: 10.1007/s13311-016-0501-z.

12.

Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models.

Huang P, Almeciga-Pinto I, Jarpe M, van Duzer JH, Mazitschek R, Yang M, Jones SS, Quayle SN.

Oncotarget. 2017 Jan 10;8(2):2694-2707. doi: 10.18632/oncotarget.13738.

13.

Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2.

Shearstone JR, Golonzhka O, Chonkar A, Tamang D, van Duzer JH, Jones SS, Jarpe MB.

PLoS One. 2016 Apr 13;11(4):e0153767. doi: 10.1371/journal.pone.0153767. eCollection 2016.

14.

Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice.

Regna NL, Vieson MD, Luo XM, Chafin CB, Puthiyaveetil AG, Hammond SE, Caudell DL, Jarpe MB, Reilly CM.

Clin Immunol. 2016 Jan;162:58-73. doi: 10.1016/j.clim.2015.11.007. Epub 2015 Nov 22.

15.

Pharmocologic treatment with histone deacetylase 6 inhibitor (ACY-738) recovers Alzheimer's disease phenotype in amyloid precursor protein/presenilin 1 (APP/PS1) mice.

Majid T, Griffin D, Criss Z 2nd, Jarpe M, Pautler RG.

Alzheimers Dement (N Y). 2015 Oct 11;1(3):170-181. doi: 10.1016/j.trci.2015.08.001. eCollection 2015 Nov.

16.

Influence of canonical structure determining residues on antibody affinity and stability.

Clark LA, Demarest SJ, Eldredge J, Jarpe MB, Li Y, Simon K, van Vlijmen HW.

J Struct Biol. 2014 Feb;185(2):223-7. doi: 10.1016/j.jsb.2013.08.009. Epub 2013 Aug 29.

PMID:
23994046
17.

Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance.

Cook C, Carlomagno Y, Gendron TF, Dunmore J, Scheffel K, Stetler C, Davis M, Dickson D, Jarpe M, DeTure M, Petrucelli L.

Hum Mol Genet. 2014 Jan 1;23(1):104-16. doi: 10.1093/hmg/ddt402. Epub 2013 Aug 19.

18.

Antidepressant-like properties of novel HDAC6-selective inhibitors with improved brain bioavailability.

Jochems J, Boulden J, Lee BG, Blendy JA, Jarpe M, Mazitschek R, Van Duzer JH, Jones S, Berton O.

Neuropsychopharmacology. 2014 Jan;39(2):389-400. doi: 10.1038/npp.2013.207. Epub 2013 Aug 19.

19.

Antibody humanization by redesign of complementarity-determining region residues proximate to the acceptor framework.

Hanf KJ, Arndt JW, Chen LL, Jarpe M, Boriack-Sjodin PA, Li Y, van Vlijmen HW, Pepinsky RB, Simon KJ, Lugovskoy A.

Methods. 2014 Jan 1;65(1):68-76. doi: 10.1016/j.ymeth.2013.06.024. Epub 2013 Jun 28.

PMID:
23816785
20.

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N.

Blood. 2012 Mar 15;119(11):2579-89. doi: 10.1182/blood-2011-10-387365. Epub 2012 Jan 19.

21.

Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4.

Shapiro RI, Plavina T, Schlain BR, Pepinsky RB, Garber EA, Jarpe M, Hochman PS, Wehner NG, Bard F, Motter R, Yednock TA, Taylor FR.

J Pharm Biomed Anal. 2011 Apr 28;55(1):168-75. doi: 10.1016/j.jpba.2011.01.006. Epub 2011 Jan 19.

PMID:
21300512
22.

An antibody loop replacement design feasibility study and a loop-swapped dimer structure.

Clark LA, Boriack-Sjodin PA, Day E, Eldredge J, Fitch C, Jarpe M, Miller S, Li Y, Simon K, van Vlijmen HW.

Protein Eng Des Sel. 2009 Feb;22(2):93-101. doi: 10.1093/protein/gzn072. Epub 2008 Dec 10.

PMID:
19074157
23.

Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.

Lukashev M, LePage D, Wilson C, Bailly V, Garber E, Lukashin A, Ngam-ek A, Zeng W, Allaire N, Perrin S, Xu X, Szeliga K, Wortham K, Kelly R, Bottiglio C, Ding J, Griffith L, Heaney G, Silverio E, Yang W, Jarpe M, Fawell S, Reff M, Carmillo A, Miatkowski K, Amatucci J, Crowell T, Prentice H, Meier W, Violette SM, Mackay F, Yang D, Hoffman R, Browning JL.

Cancer Res. 2006 Oct 1;66(19):9617-24.

24.

Structure activity relationships of monocyte chemoattractant proteins in complex with a blocking antibody.

Reid C, Rushe M, Jarpe M, van Vlijmen H, Dolinski B, Qian F, Cachero TG, Cuervo H, Yanachkova M, Nwankwo C, Wang X, Etienne N, Garber E, Bailly V, de Fougerolles A, Boriack-Sjodin PA.

Protein Eng Des Sel. 2006 Jul;19(7):317-24. Epub 2006 May 8.

PMID:
16682434
25.

Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design.

Clark LA, Boriack-Sjodin PA, Eldredge J, Fitch C, Friedman B, Hanf KJ, Jarpe M, Liparoto SF, Li Y, Lugovskoy A, Miller S, Rushe M, Sherman W, Simon K, Van Vlijmen H.

Protein Sci. 2006 May;15(5):949-60. Epub 2006 Apr 5.

26.

Gene profiling in atherosclerosis reveals a key role for small inducible cytokines: validation using a novel monocyte chemoattractant protein monoclonal antibody.

Lutgens E, Faber B, Schapira K, Evelo CT, van Haaften R, Heeneman S, Cleutjens KB, Bijnens AP, Beckers L, Porter JG, Mackay CR, Rennert P, Bailly V, Jarpe M, Dolinski B, Koteliansky V, de Fougerolles T, Daemen MJ.

Circulation. 2005 Jun 28;111(25):3443-52. Epub 2005 Jun 20.

PMID:
15967845
27.

Antibody blockade of the Cripto CFC domain suppresses tumor cell growth in vivo.

Adkins HB, Bianco C, Schiffer SG, Rayhorn P, Zafari M, Cheung AE, Orozco O, Olson D, De Luca A, Chen LL, Miatkowski K, Benjamin C, Normanno N, Williams KP, Jarpe M, LePage D, Salomon D, Sanicola M.

J Clin Invest. 2003 Aug;112(4):575-87.

28.

Apoptosis stimulated by the 91-kDa caspase cleavage MEKK1 fragment requires translocation to soluble cellular compartments.

Schlesinger TK, Bonvin C, Jarpe MB, Fanger GR, Cardinaux JR, Johnson GL, Widmann C.

J Biol Chem. 2002 Mar 22;277(12):10283-91. Epub 2002 Jan 8.

29.

Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human.

Widmann C, Gibson S, Jarpe MB, Johnson GL.

Physiol Rev. 1999 Jan;79(1):143-80. Review.

30.

Anti-apoptotic versus pro-apoptotic signal transduction: checkpoints and stop signs along the road to death.

Jarpe MB, Widmann C, Knall C, Schlesinger TK, Gibson S, Yujiri T, Fanger GR, Gelfand EW, Johnson GL.

Oncogene. 1998 Sep 17;17(11 Reviews):1475-82. Review.

31.

MEK kinase 1, a substrate for DEVD-directed caspases, is involved in genotoxin-induced apoptosis.

Widmann C, Gerwins P, Johnson NL, Jarpe MB, Johnson GL.

Mol Cell Biol. 1998 Apr;18(4):2416-29.

32.

[D-Arg1,D-Phe5,D-Trp7,9,Leu11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors.

Jarpe MB, Knall C, Mitchell FM, Buhl AM, Duzic E, Johnson GL.

J Biol Chem. 1998 Jan 30;273(5):3097-104.

33.

Preferential activation of the p46 isoform of JNK/SAPK in mouse macrophages by TNF alpha.

Chan ED, Winston BW, Jarpe MB, Wynes MW, Riches DW.

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13169-74.

34.
35.

MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases?

Fanger GR, Gerwins P, Widmann C, Jarpe MB, Johnson GL.

Curr Opin Genet Dev. 1997 Feb;7(1):67-74. Review.

PMID:
9024636
36.

Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death.

Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL.

J Biol Chem. 1996 Feb 9;271(6):3229-37.

37.

Nuclear lipid metabolism in NEST: Nuclear Envelope Signal Transduction.

Raben DM, Jarpe MB, Leach KL.

J Membr Biol. 1994 Oct;142(1):1-7. Review.

PMID:
7707346
38.

A V lambda x-bearing monoclonal antibody with similar specificity and sequence to encephalitogenic T cell receptors.

Maier CC, Galin FS, Jarpe MA, Jackson P, Krishna NR, Gautam AM, Zhou SR, Whitaker JN, Blalock JE.

J Immunol. 1994 Aug 1;153(3):1132-40.

PMID:
7517973
39.

Predicted structural motif of IFN tau.

Jarpe MA, Johnson HM, Bazer FW, Ott TL, Curto EV, Krishna NR, Pontzer CH.

Protein Eng. 1994 Jul;7(7):863-7.

PMID:
7971949
40.

How interferons fight disease.

Johnson HM, Bazer FW, Szente BE, Jarpe MA.

Sci Am. 1994 May;270(5):68-75. Review. No abstract available.

PMID:
8197446
41.
42.

Binding site on the murine IFN-gamma receptor for IFN-gamma has been identified using the synthetic peptide approach.

VanVolkenburg MA, Griggs ND, Jarpe MA, Pace JL, Russell SW, Johnson HM.

J Immunol. 1993 Dec 1;151(11):6206-13.

PMID:
8245462
43.

The structure of a myelin basic protein-associated idiotope.

Maier CC, LeBoeuf RD, Zhou SR, Whitaker JN, Jarpe MA, Blalock JE.

J Neuroimmunol. 1993 Jul;46(1-2):235-43.

PMID:
7689590
44.

Solution structure of trypsin modulating oostatic factor is a left-handed helix.

Curto EV, Jarpe MA, Blalock JE, Borovsky D, Krishna NR.

Biochem Biophys Res Commun. 1993 Jun 15;193(2):688-93.

PMID:
8512567
45.

Proton NMR sequence-specific assignments and secondary structure of a receptor binding domain of mouse gamma-interferon.

Sakai TT, Jablonsky MJ, DeMuth PA, Krishna NR, Jarpe MA, Johnson HM.

Biochemistry. 1993 Jun 1;32(21):5650-5.

PMID:
8504085
47.

Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.

Soos JM, Russell JK, Jarpe MA, Pontzer CH, Johnson HM.

Biochem Biophys Res Commun. 1993 Mar 31;191(3):1211-7.

PMID:
8466498
48.

Alpha-thrombin stimulates nuclear diglyceride levels and differential nuclear localization of protein kinase C isozymes in IIC9 cells.

Leach KL, Ruff VA, Jarpe MB, Adams LD, Fabbro D, Raben DM.

J Biol Chem. 1992 Oct 25;267(30):21816-22.

49.

Nursing care of patients receiving long-term infusion of neuromuscular blocking agents.

Jarpe MB.

Crit Care Nurse. 1992 Oct;12(7):58-63. No abstract available.

PMID:
1478105
50.

The N-terminus and C-terminus of IFN-gamma are binding domains for cloned soluble IFN-gamma receptor.

Griggs ND, Jarpe MA, Pace JL, Russell SW, Johnson HM.

J Immunol. 1992 Jul 15;149(2):517-20.

PMID:
1385606

Supplemental Content

Support Center